Experimental Assessment of 3- meta -Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors  in silico  and  in vivo  Models

Yu. V. Meshkova; Мешкова Ю. В.; D. S. Baev; Баев Д. С.; I. V. Sorokina; Сорокина И. В.; I. I. Popadyuk; Попадюк И. И.; O. V. Salomatina; Саломатина О. В.; N. A. Zhukova; Жукова Н. А.; T. G. Tolstikova; Толстикова Т. Г.; N. F. Salakhutdinov; Салахутдинов Н. Ф.

doi:10.31857/S0132342323010189

Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models

Authors: Meshkova Y.V.¹, Baev D.S.¹, Sorokina I.V.¹, Popadyuk I.I.¹, Salomatina O.V.¹, Zhukova N.A.¹, Tolstikova T.G.¹, Salakhutdinov N.F.¹
Affiliations:
1. Novosibirsk Institute of Organic Chemistry SB RAS
Issue: Vol 49, No 1 (2023)
Pages: 79-92
Section: Articles
URL: https://rjmseer.com/0132-3423/article/view/670708
DOI: https://doi.org/10.31857/S0132342323010189
EDN: https://elibrary.ru/GGKQXV
ID: 670708

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

5-α-Reductase (5-AR) inhibitors are considered the most effective drugs in the treatment of proliferative processes in prostate adenoma. These include two synthetic azasteroids – finasteride and dutasteride, which cause side effects in conditions of long-term course therapy which form the disorders of sexual function in men. We propose 3-meta-pyridine-1,2,4-oxadiazole derivative of deoxycholic acid as prototype of low-toxic 5-AR inhibitors. It has been shown that the new agent is able to penetrate the 5-AR binding site through the formation of covalent adducts with NADP-H, like finasteride. At the same time, both ligands have comparable with the target binding energy values (–20 and –15 kcal/mol, respectively, for finasteride and target compound). In experiments on testosterone and sulpiride models of BPH, we have found that intragastric administration of DCA derivative at a dose of 20 mg/kg and finasteride at a dose of 10 mg/kg has a similar prostatoprotective effect by reducing proliferative processes in the glandular epithelium and prostate stroma of rats. The new agent is less toxic than finasteride: the LD₅₀ value in mice is >1500 mg/kg versus 1060 mg/kg in finasteride. Based on the results obtained, the 3-meta-pyridine-1,2,4-oxadiazole derivative of deoxycholic acid can be considered as a promising candidate for preclinical testing.

Keywords

5-\(\alpha \)-reductase inhibitors, oxadiazole derivatives of deoxycholic acid, toxicity, benign prostatic hyperplasia, rats

References

Launer B.M., McVary K.T., Ricke W.A., Lloyd G.L. // BJU Int. 2021. V. 127. P. 722–728. https://doi.org/10.1111/bju.15286
Lim K.B. // Asian J. Urol. 2017. V. 4. P. 148–151. https://doi.org/10.1016/j.ajur.2017.06.004
Carson C., Rittmaster R. // Urology. 2003. V. 61. P. 2–7. https://doi.org/10.1016/S0090-4295(03)00045-1
Vickman R.E., Franco O.E., Moline D.C., Vander Griend D.J., Thumbikat P., Hayward S.W. // Asian J. Urol. 2020. V. 7. P. 191–202. https://doi.org/10.1016/j.ajur.2019.10.003
La Vignera S., Condorelli R.A., Russo G.I., Morgia G., Calogero A.E. // Andrology. 2016. V. 4. P. 404–411. https://doi.org/10.1111/andr.12186
Thiruchelvam N. // Renal and Urological Surgery III. 2014. V. 32. P. 314–322. https://doi.org/10.1016/j.mpsur.2014.04.006
Gravas S., Cornu J.N., Drake M.J., Gacci M., Gratzke C., Herrmann T.R.W., Madersbacher S., Mamoulakis C., Tikkinen K.A.O. // Eur. Assoc. Urol. 2018. https:// uroweb.org/wp-content/uploads/EAU-Guidelines-on-the-Management-of-Non-neurogenic-Male-LUTS-2018-large-text.pdf
Kim E.H., Brockman J.A., Andriole G.L. // Asian J. Urol. 2018. V. 5. P. 28–32. https://doi.org/10.1016/j.ajur.2017.11.005
Сорокина И.В., Попадюк И.И., Жукова Н.А., Низомов С.А., Мешкова Ю.В., Баев Д.С., Саломатина О.В., Толстикова Т.Г., Салахутдинов Н.Ф. // Патент RU 2 750 488 C1, 2021.
Huang Y., Cui J., Jia L., Gan C., Song H., Zeng C., Zhou A. // Molecules. 2013. V. 18. P. 7436–7447. https://doi.org/10.3390/molecules18077436
Verzele D., Madder A. // J. Org. Chem. 2007. P. 1793–1797. https://doi.org/10.1002/ejoc.200600972
Schrodinger Small Molecule Drug Discovery Suite. 2017. https://www.schrodinger.com
Harder E., Damm W., Maple J., Wu C., Reboul M., Xiang J.Y., Wang L., Lupyan D., Dahlgren M.K., Knight J.L., Kaus J., Cerutti D., Krilov G., Jorgensen W., Abel R., Friecner R. // J. Chem. Theory Comput. 2016. V. 12. P. 281–296. https://doi.org/10.1021/acs.jctc.5b00864
Xiao Q., Wang L., Supekar S., Shen T., Liu H., Ye F., Huang J., Fan H., Wei Z., Zhang C. // Nat. Commun. 2020. V. 11. P. 1–10. https://doi.org/10.1038/S41467-020-19249-Z
Makino C., Watanabe A., Deguchi T., Shiozawa H., Schreck I., Rozehnal V., Ishizuka T., Watanabe N., Ando O., Murayama N., Yamazaki H. // Xenobiotica. 2019. V. 49. P. 961–969. https://doi.org/10.1080/00498254.2018.1514545
Tsalta C.D., Madatian A., Schubert E.M., Xia F., Hardesty W., Deng Y., Seymour J.L., Gorychi P.D. // Drug Metab. Dispos. 2011. V. 39. P. 1620–1632. https://doi.org/10.1124/dmd.110.036467
Makridakis N., Akalu A., Reichardt J.K.V. // Oncogene. 2004. V. 23. P. 7399–7405. https://doi.org/10.1038/sj.onc.1207922
Li J., Tian Y., Guo S., Gu H., Yuan Q., Xie X. // PLoS One. 2018. V. 13. P. 1–13. https://doi.org/10.1371/journal.pone.0191469
Миронов А.Н., Бунятян Н.Д. // Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К., 2012. 944 с.
Altavilla D., Minutoli L., Polito F., Irrera N., Arena S., Magno C., Rinaldi M., Burnett B.P., Squadrito F., Bitto A. // Br. J. Pharmacol. 2012. V. 167. P. 95–108. https://doi.org/10.1111/j.1476-5381.2012.01969.x
Hsu C.Y., Lin Y.S., Weng W.C., Panny L., Chen H.L., Tung M.C., Ou Y.C., Lin C.C., Yang C.H. // Life. 2021. V. 11. P. 743. https://doi.org/10.3390/life11080743
Veeresh Babu S.V., Veeresh B., Patil A.A., Warke Y.B. // Eur. J. Pharmacol. 2010. V. 626. P. 262–265. https://doi.org/10.1016/j.ejphar.2009.09.037
Сорокина И.В., Жукова Н.А., Мешкова Ю.В., Баев Д.С., Толстикова Т.Г., Бакарев М.А., Лушникова Е.Л. // Бюллетень экспериментальной биологии и медицины. 2022. Т. 173. С. 656–663. https://doi.org/10.47056/0365-9615-2022-173-5-656-663
Van Coppenolle F., Slomianny C., Carpentier F., Le Bourhis X., Achidouch A., Croix D., Legrand G., Dewailly E., Fournier S., Cousse H., Authie D., Raynaud J.-P., Beauvillain J.-C., Dupouy J.-P., Prevarskaya N. // Am. J. Physiol. Endocrinol. Metab. 2001. V. 280. P. 120–129. https://doi.org/10.1152/ajpendo.2001.280.1.e120
Тюзиков И.А., Мартов А.Г. // Андрология. 2012. № 3. С. 39–47.
Han Y.T., Yun H. // Org. Prep. Proc. Int. 2017. V. 49. P. 163–168. https://doi.org/10.1080/00304948.2017.1291005
Shruthi N., Poojary B., Kumar V., Hussain M.M., Rai V.M., Pai V.R., Bhat M., Revannasiddappa B.C. // RSC Adv. 2016. V. 6. P. 8303–8316. https://doi.org/10.1039/C5RA23282A
Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., Mainz D.T. // J. Med. Chem. 2006. V. 49. P. 6177–6196. https://doi.org/10.1021/jm051256o
Biovia Dicovery Studio Visualizer. 2016. https://discover.3ds.com/discovery-studio-visualizer-download
Jeon W.-Y., Kim O.S., Seo C.-S., Jin S.E., Kim J.-A., Shin H.-K., Kim Y., Lee Y. // BMC Complement. Altern. Med. 2017. V. 17. P. 384. https://doi.org/10.1186/s12906-017-1877-y
Автандилов Г.Г. // Медицинская морфометрия. М.: Медицина, 1990. 384 с.
Саноцкий И.В. // Методы определения токсичности и опасности химических веществ (токсикометрия). Москва: Медицина, 1970. 99 с.